The Institute of Cancer Research, London, is one of the world’s most influential cancer research institutes, with an outstanding record of achievement dating back more than 100 years. We provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today, The Institute of Cancer Research (ICR) leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.
The Cancer Research UK Cancer Therapeutics Unit (CTU), within the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The CTU’s exciting goal is to discover high quality small molecule drug candidates and to progress these to clinical trial. All the scientific disciplines are in place to make this possible, including assay development and screening, medicinal chemistry, biology, structural biology, metabolism and clinical specialists.
Two postdoctoral positions in Structural Biology (ID 758) are available in Dr Rob van Montfort’s Hit Discovery and Structural Design (HDSD) Team within the CTU.
The postdoctoral researchers in structural biology will be involved in X-ray crystallography, fragment-based screening and structure-based drug design and will be responsible for protein _expression_, purification, crystallisation, structure determination and structural analysis of protein-ligand complexes from one of the CTU’s drug discovery programmes. The successful candidates will also be part of the Division of Structural Biology, in which the crystallographers in Dr van Montfort’s team are embedded, and will have access to state of the art protein crystallography and electron microscopy facilities, including an in-house X-ray source and excellent access to synchrotrons. The successful candidate will interact closely with the biology, computational chemistry and medicinal chemistry teams at the CTU, and will therefore be expected to work across the two sites in Chelsea, London and Sutton, Surrey. Applicants must have a PhD in a biological or physical science, and experience in macromolecular crystallography (to include protein biochemistry, protein crystallisation, & protein crystallography). Experience in molecular biology, protein _expression_ in insect cells, structure-based drug design, and/or biophysics will be an advantage. The starting salary for the positions will be in the range £31,023 to £39,473 p.a. inclusive (based on previous post-doctoral experience). One position is funded for one year and one is funded for two years. Applicants will automatically be considered for both positions. Informal enquiries can be made via email to firstname.lastname@example.org or email@example.com. Closing date is 07/07/2019.
Please DO NOT send your application to Dr van Montfort, or Dr Le Bihan. Applications will only be considered if made via the e-recruitment system on our website www.icr.ac.uk.
The Institute of Cancer Research: Royal Cancer Hospital, a charitable Company Limited by Guarantee, Registered in England under Company No. 534147 with its Registered Office at 123 Old Brompton Road, London SW7 3RP.
This e-mail message is confidential and for use by the addressee only. If the message is received by anyone other than the addressee, please return the message to the sender by replying to it and then delete the message from your computer and network.
To unsubscribe from the CCP4BB list, click the following link: